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ABSTRACT
Objective: There are limited studies concerning the eco-
nomic burden of osteoporosis in the Medicaid population.
This study estimated the direct cost of osteoporosis-related
fractures (OPFx) to state Medicaid budgets.
Methods: This retrospective analysis utilized Medicaid
claims databases from three states, which included approxi-
mately 8 million Medicaid recipients. The study sample had
at least one claim for an osteoporosis diagnosis (733.0x)
between January 1, 2000 and December 31, 2001. Beneﬁci-
aries with a fracture and a diagnosis of osteoporosis were
assigned to the case cohort. A propensity score-based match-
ing method was used to select a cohort of controls with oste-
oporosis but without a fracture. An exponential conditional
mean model was used to estimate the incremental annual
cost associated with fractures.
Results: The study cohort (n = 7626) and a 1:1 matched
control group were identiﬁed. The study cohort was 85.8%
female, had an average age of 65 years, were 53.2% white,
and 48.9% were eligible for Medicare. There were signiﬁcant
increases (all P < 0.05) from the preperiod to study period
for this cohort in the proportion that had at least one hos-
pital admission (14.0% vs. 26.5%), nursing home admission
(9.2% vs. 17.2%), home health (39.1% vs. 49.3%), or emer-
gency room visit (21.3% vs. 31.9%). In contrast, the control
cohort had very little increase in utilization. The regression-
adjusted incremental cost for osteoporosis-related expenses
in the year after fracture was estimated at $4007 per patient.
The estimated incremental cost was $5370 for the subset of
patients who were eligible for Medicare.
Conclusion: The economic burden of osteoporosis-related
fractures on state Medicaid budgets is substantial.
Keywords: claims analysis, fracture, Medicaid, osteoporosis.
Introduction
Osteoporosis places a large medical and economic
burden on the health-care system. Low bone mass and
deterioration of the skeletal microarchitecture result-
ing from osteoporosis increase the risk of fragility frac-
tures [1]. In 1994, the World Health Organization
(WHO) Study Group established formal diagnostic cri-
teria for osteoporosis based on bone mineral density
(BMD) and the presence of a fragility fracture [1]. The
four categories include normal, osteopenia, osteoporo-
sis, and established/severe osteoporosis. The WHO
deﬁnes osteoporosis as a BMD score of at least 2.5
standard deviations lower than the young-adult nor-
mal mean, and osteopenia or low bone mass as a BMD
score between 1 and 2.5 standard deviations lower
than the young-adult normal mean [1,2].
As of 2002, approximately 8 million postmenopau-
sal women in the United States received a diagnosis of
osteoporosis. An additional 22 million had low bone
mass indicating they were at high risk of developing
the disease. More than 2 million individuals experience
an osteoporosis-related fracture (i.e., established/
severe osteoporosis) each year in the United States [3].
In the United States, nearly one-third of patients with
a hip fracture are admitted to nursing facilities in the
year after a fracture, and the incidence mortality rate
increases to 20% during that year [4,5]. Vertebral frac-
tures are the most common osteoporotic fracture, with
more than 700,000 annual cases. Like hip fractures,
vertebral fractures are also associated with increased
mortality and morbidity [6]. Epidemiological data
show that women more than 50 years old with low
bone mass have a 42% lifetime risk of a fracture, while
white women more than 50 years old have nearly a
40% lifetime risk of hip, spine, or distal forearm frac-
tures [7,8]. As 20% of women who already have a ver-
tebral fracture will have another vertebral fracture
within 1 year, there is a potential “fracture cascade,”
which demonstrates the need for effective prevention
and treatment strategies [9].
Severe or established osteoporosis is deﬁned by the
WHO as a BMD score of at least 2.5 standard devia-
tions lower than the young-adult normal mean and
one or more fragility fractures. Patients with severe
osteoporosis require treatment and subsequent care
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that results in substantial economic burden [10–12]. In
a study of a commercial claims database, patients with
a diagnosis of osteoporosis and a concurrent fracture
had more than twice the annual health-care expendi-
tures compared with patients with osteoporosis and
without a fracture ($15,942 vs. $6476) [13]. In a study
of the burden of osteoporosis in California during
1998, an estimated $2.4 billion in direct health costs
and more than $4 million in lost productivity were
attributed to osteoporosis [14]. In addition, 59% of all
direct medical costs associated with osteoporosis were
associated with nursing home expenses [14]. Sasser
et al. estimated that female employees with osteoporo-
sis would incur more than $4000 in lost productivity
as compared with approximately $2300 for the typical
older female employee [15]. On a national level, the
burden of osteoporosis was estimated in 1995 at $13.8
billion per year [16]. The total, annual cost burden,
including opportunity costs, was estimated at $34.0
billion [17].
Most of the claims-based analyses for osteoporosis
have used data from commercial plans. The direct cost
for osteoprosis-related fractures, however, is largely
covered by public payers. Medicare and Medicaid
covered 48% and 24% of these medical expendi-
tures, respectively [18]. One recently published study
included Medicare Supplemental and Coordination of
Beneﬁts data along with commercial plans [15]. Med-
icaid beneﬁciaries are of particular interest because
they have longer inpatient stays and higher total hos-
pital charges than Medicare beneﬁciaries [19]. Private
and self-pay patients paid less for their care and had
shorter lengths of hospital stay [19]. Medicaid beneﬁ-
ciaries, when other factors such as age, race, and spe-
cialty of treating physician are controlled for, were
found to be 55% less likely to receive an osteoporosis-
related prescription [20]. There are limited studies
concerning osteoporosis in the Medicaid population,
with most of these studies focusing on outpatient care
[20,21] or focused only on hip fractures [22,23].
Results from 1993 Medicaid data indicated that
expenditures during the month of a fracture signiﬁ-
cantly increased immediately after the fracture but
returned to the baseline trend within a 12-month
period [24]. The primary objective of the current study
is to investigate the annual direct medical expenditures
associated with osteoporosis-related fractures that are
covered by Medicaid. An additional objective was to
investigate the drivers of the cost to Medicaid by
examining the differences in resource utilization.
Materials and Methods
Data Source
This retrospective analysis used Medicaid claims for
services incurred from January 1, 1999 through
December 31, 2002 from three states. The database
contains the inpatient, outpatient, outpatient prescrip-
tion drug, and long-term care claims experience of
approximately 8 million Medicaid recipients covered
under both fee-for-service and capitated health plans.
All services delivered to patients dually eligible for
both Medicaid and Medicare are included in the data-
base as long as Medicaid paid some portion of the
claim. The Medicaid paid portion of the bill is deline-
ated from the Medicare paid portion of the claim.
Because Medicare requires a deductible or coinsurance
on almost all services, the vast majority of services
received by Medicaid beneﬁciaries should be incorpo-
rated into the database. No personally identiﬁable
information is available in the database (i.e., names,
social security numbers, medical record numbers,
addresses, birth dates); however, persons can be
tracked longitudinally using encrypted identiﬁcation
numbers. Medstat’s contracts with the state Medicaid
agencies that provide these data for research purposes
preclude the release of the states’ identities.
Study Population
Individuals with 24 months of continuous enrollment
and at least one claim containing a diagnosis of
osteoporosis (733.0x) between January 1, 2000 and
December 31, 2001 were identiﬁed for the initial study
sample population. Persons with evidence of malig-
nant neoplasm or carcinoma (International Classiﬁca-
tion of Diseases, 9th Edition (ICD-9) 140.x−208.x,
230.x−239.x), with the exception of melanoma (ICD-
9 172.x, 173.x), or Paget’s disease of bone (ICD-9
731.0) between 1999 and 2002 were excluded.
Identiﬁed patients were classiﬁed into one of two
groups. The osteoporosis with fracture cohort (OPFx)
consisted of patients with a claim for a fracture and at
least one claim containing an osteoporosis diagnosis
code during the observation period. The osteoporosis-
related fracture codes were adapted from the National
Committee for Quality Assurance guidelines on oste-
oporosis [25]. The remaining patients with an oste-
oporosis diagnosis but no claims for osteoporosis-
related fractures were classiﬁed as the osteoporosis
without fracture (OP) cohort. The patient selection cri-
teria are summarized as a ﬂow chart in Figure 1.
For patients in the OPFx cohort, the service date of
the ﬁrst observed medical claim with an osteoporosis-
related fracture diagnosis was assigned as the index
date. The service date of the ﬁrst observed medical
claim with an osteoporosis diagnosis after January 1,
2000 was assigned as the index date for the cohort
without fracture. Patients in the OP cohort may con-
tain both newly diagnosed and patients with a history
of osteoporosis, because no “clean” period before the
index date was required. By using these criteria, we
hoped to gain a wide representation of osteoporosis
patients at all stages of the disease. All qualifying
patients in both cohorts were required to have at least
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12 months of continuous enrollment before and after
the index date.
Outcomes Measures and Covariates
Annual rates of health-care utilization and expendi-
tures were categorized by service area (hospita-
lizations, nursing home stays, home health visits,
emergency department services, outpatient services,
and outpatient pharmaceutical prescriptions) in the
year before and year after the index date. Only those
patients  with  an  indemnity/fee-for-service  type  of
plan were included in the summary of utilization and
expenditures. Claims were further categorized as being
osteoporosis-related and non–osteoporosis-related in
the two osteoporosis cohorts. Osteoporosis-related
claims were those with a coded primary diagnosis of
osteoporosis. In the cohort with fractures, claims with
one of the speciﬁed fracture diagnoses were also clas-
siﬁed as osteoporosis-related costs. Nursing home care
was classiﬁed as osteoporosis-related if there was at
least one claim with a diagnosis of osteoporosis or
fracture at any point during a nursing home episode
(until a gap of more than 60 days of nursing home
services). Expenditures documented in the database
include the total gross reimbursed payment to a pro-
vider for speciﬁc services before application of deduct-
ibles, copayments, and coordination of beneﬁts, but
after applying pricing guidelines such as fee schedules
and discounts. Expenditures for services delivered in
1999 through 2001 were inﬂated to 2002 equivalents
using changes in the medical component of the Con-
sumer Price Index between these years and 2002.
Baseline demographic characteristics for the sample
included sex, age, insurance plan type, Medicare eligi-
bility, race, and Medicaid eligibility reason. A Charl-
son comorbidity index (CCI) score was also created for
each patient as a way to measure concurrent comor-
bidity [26]. Among the cohort of patients with frac-
ture, the fracture location(s) were also identiﬁed, as
well as the number of fractures incurred during the
study period.
Statistical Analyses
Descriptive summary statistics on health-care utiliza-
tion, expenditures, and key demographic and clinical
characteristics for the osteoporosis cohort were pro-
duced, stratiﬁed by fracture status. Nonparametric
Mann–Whitney U-tests were used to assess statistical
differences in utilization and expenditure statistics
across the cohorts. Chi-square tests and t tests were
used to determine whether differences in proportions
and rates, respectively, varied across the groups.
In addition to the nonfracture osteoporosis cohort,
a propensity score matched control group with a sim-
ilar likelihood of acquiring a fracture was also created
for comparison of health-care expenditures. Using the
osteoporotic without fracture group as the sample
pool, a control was matched to each patient with an
osteoporotic fracture based on propensity scores. A
logistic regression model, using osteoporotic fracture
in the study period as the dependent variable, was used
to assign each individual with and without fracture a
propensity score. Independent variables in the model
included age, race, geographic location, sex, CCI
score, plan type, osteoporosis medication use, and
Medicare eligibility. A control was matched to each
case by this score using the Nearest Neighbor Match-
ing (Without Replacement) technique, which identiﬁes
Figure 1 Schematic of patient ﬂow.
Medicaid claims database from 3 states, contains 
approximately 8 million Medicaid recipients
Patients with 24 months of data, an osteoporosis diagnosis and excluding 
those with Paget’s disease of bone, malignant neoplasm or carcinoma (except 
melanoma)
N = 38,298
Patients matched 1:1 (see methods for details) to 
the cohort with osteoporosis-related fractures
N = 7,626
Patients with 
osteoporosis-related 
fractures (OPFx)
N = 7,626
20%
Patients without 
osteoporosis-related 
fractures (OP)
N = 30,672
80%
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each case and searches for the control with the closest
propensity score, i.e., the Nearest Neighbor.
To evaluate the incremental economic impact of
osteoporotic facture in the osteoporosis population,
controlling for other factors not addressed by the pro-
pensity score match, a series of second-stage 12-month
expenditure models were estimated. The dependent
variables were annual overall expenditures in the 12-
month study period and annual osteoporosis-related
expenditures in the 12-month study period. Covariates
in the model included presence of fracture, demo-
graphic characteristics, geographic location, health
plan type, and baseline health characteristics. Baseline
health characteristics included the CCI score in the
preperiod, other comorbidity indicator variables, and
variables describing the presence of osteoporosis-
related medications in the preperiod. We did not use
interaction terms in the models, as they were not rel-
evant to the research objective. One set of models
included the osteoporotic fracture cohort (OPFx) ver-
sus all osteoporosis patients (OP) in the study popula-
tion. Another set of models included osteoporotic
fracture cohort (OPFx) versus the propensity score
matched osteoporosis patients.
For the multivariate models, ordinary least squares
(OLS) models with log transformation and exponen-
tial conditional mean (ECM) models were considered
[27–29]. A White–Huber test conﬁrmed the heteroske-
dasticity and the data were found to be heavily tailed.
Thus, an ECM model was determined as the appropri-
ate functional form for the expenditure models, and
OLS regression was used only for comparison. An
ECM regression is a generalized linear model with a
log link function; its use avoids many of the pitfalls of
retransformation. The ECM model produced parame-
ter estimates similar to those found in an OLS regres-
sion model. Nevertheless, because the exponential
model is nonlinear, the estimated regression coefﬁ-
cients do not equal the marginal or incremental effect
of a one-unit change in the covariate of interest on the
conditional mean. Parameter estimates from the mod-
els were used to compute the marginal effects of oste-
oporotic fracture. Among the subset of patients with
osteoporotic fracture, we also estimated total costs by
primary fracture location. A Park test was used to
select the Gamma family of model; the standard devi-
ation was found to be proportional to the mean.
Descriptive analyses were conducted using SAS version
8.0 (SAS Institute Inc., Cary, NC) and multivariate
analyses were conducted using STATA Version 8 soft-
ware (StataCorp, College Station, TX).
Results
State Medicaid and Study Population Characteristics
As the identity of the states cannot be revealed because
of conﬁdentiality agreements, we brieﬂy summarize
the characteristics of the beneﬁciaries in these states so
that the external applicability of the results can be
understood. For two of the states, the majority of the
Medicaid beneﬁciaries were less than 18 years old.
Indemnity coverage was the primary form of insurance
in two of the states (67.55% and 50.14%), while the
other state more commonly used primary care case
management (65.93%). In 2002, less than 1% of the
beneﬁciaries  in  any  of  the  three  states  had  a  claim
for osteoporosis or severe osteoporosis (range 0.22–
0.76%). The cost to Medicaid for these patients, how-
ever, was disproportionately high. For example, in one
state, about 0.76% of the Medicaid recipients had a
claim related to osteoporosis, but these patients
accounted for nearly 4% of the Medicaid medical
claim outlays.
The demographic characteristics of the study pop-
ulation are summarized in Table 1. The OPFx cohort
had a mean age of 65 years, almost 49% were eligible
to receive Medicare, and 85.8% were female. For com-
parison, the Medicaid recipients with an osteoporosis
diagnosis but without a fracture (OP cohort) were
more than 2 years older, 51.6% were Medicare-eligi-
ble, and 88.2% were female. More than 83% of both
the OP and OPFx cohorts had indemnity insurance
coverage. The patients with capitated insurance cover-
age were slightly younger and had less comorbidity
(not shown). A higher percentage of individuals with
an osteoporosis-related fracture were white, although
race data were missing or listed as unknown in nearly
one-quarter of the population. Hip/pelvis (31.3%),
clinical vertebral (17.1%), and forearm/wrist (13.8%)
Table 1 Demographic characteristics of patients with oste-
oporosis
Characteristic OP OPFx Matched control
N 30,672 7,626 7,626
Age (mean years) 67.54* 65.14 65.49
Female (%) 88.20* 85.84 85.62
Eligible for Medicare (%) 51.63* 48.90 47.80
Plan type (%)
Indemnity 83.12 83.43 84.26
PCCM 4.93 5.28 5.26
Managed care 11.95 11.29 10.48
Medicaid eligibility reason (%)
Aged/SSI 49.57* 40.01 39.39
Disabled/SSI 42.30* 51.99 53.32
TANF/AFDC 5.49* 6.12 5.55
Other 2.64 1.88 1.74
Race/ethnic group (%)
White 41.15* 53.15 54.35
Asian 19.65* 11.11 10.23
Black 5.69 5.99 5.77
Hispanic 5.17 4.89 4.66
Unknown 28.17* 24.51 24.73
Propensity score (mean) NA 0.253 0.244
*P < 0.05 for comparison of cohort without fractures (OP) to cohort with fractures
(OPFx). No signiﬁcant differences were seen for comparison of cohort without frac-
tures propensity score matched (matched control) with cohort with fractures
(OPFx).
NA, not applicable; PCCM, primary care case management; SSI, supplemental secu-
rity income; TANF/AFDC, temporary assistance for needy families/aid to families
with dependent children.
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fractures accounted for more than 60% of the index
fractures in the OPFx cohort (not shown). Only 30%
of the population had a fracture in more than one loca-
tion at index or during the follow-up year (not shown).
The characteristics of the propensity score matched
control group are also summarized in Table 1. The
propensity score methodology worked well (area
under the receiver operating characteristic curve,
0.67), with the OPFx cohort and the matched control
having no signiﬁcant differences in baseline demo-
graphic and clinical characteristics after matching.
Resource Utilization and Annual Median 
Health-Care Expenditures
In Figure 2, resource utilization data for all diagnoses
are provided for the subset of patients enrolled in a fee-
for-service insurance plan. For the OPFx study cohort,
there was a signiﬁcant increase in the percentage of
beneﬁciaries, with at least one claim for hospitaliza-
tion, admission to a nursing home, visit from home
health care, visit to the emergency room, or outpatient
services from the year before the fracture (preperiod)
to the year after a fracture (study period). For the con-
trol group, signiﬁcant increases in resource utilization
were seen with nursing home, home health services,
and outpatient services. There was more utilization of
all types of health-care services in the study cohort
compared with the control cohort, both before and
during the study period, although the differences seen
with home health services in the preperiod and overall
outpatient services in the preperiod and study period
were not statistically signiﬁcant.
The subset of services that could be directly attrib-
uted to osteoporosis is reported in Table 2. For the
OPFx study cohort, there was a large increase in the
proportion of patients with claims for osteoporosis-
related services after a fracture. Most of the beneﬁci-
aries in both the OPFx group and the control group
ﬁlled a prescription related to osteoporosis or had a
claim for outpatient service.
Table 2 also shows the mean osteoporosis costs by
category among service users and for all patients in
the cohort for the preperiod and the study period.
These cost data were skewed and not normally dis-
tributed, which  is  common  for  health-care  cost
data. Total osteoporosis costs for the OPFx group
increased by $3443, while the nonfracturing cohort
had a $575 increase in costs for delivery of oste-
oporosis-related services. Thus, there was an incre-
mental increase of $2868 in osteoporosis-related
costs due to fracture in the year after the fracture. In
both cohorts, the driver of increases between pre-
and postperiod costs was spending on outpatient
service delivery; this was followed closely by
increases due to nursing home-related expenditures.
Pharmaceuticals were the only expenditures that
increased by similar amounts for the fracturing and
nonfracturing osteoporosis cohorts between the pre-
and postperiods.
Table 3 presents total expenditure comparisons for
all services delivered to the OPFx and non-OPFx
cohorts during the pre- and postperiods. The total
mean cost for the OPFx cohort increased from
$14,782 during the year before the fracture to $23,005
in the study period. The increase in Medicaid cost was
nearly $8223 per beneﬁciary without controlling for
the differences in explanatory variables. Approxi-
mately 42% ($3443 out of $8223) of the increase in
costs was directly attributable to osteoporosis-related
claims.
Marginal Effect of Fracture on Annual 
Health-Care Expenditures
Table 4 presents the parameter estimates for variables
used in the ECM model for all costs and for osteoporo-
sis-related costs. Signiﬁcant variables included having
Figure 2 Annual health-care utilization for
patients with osteoporosis enrolled in a fee-for-
service insurance plan. *P < 0.05 for compari-
son of preperiod costs to study period costs;
†P < 0.05 for comparison of propensity score
matched cohort without fractures (matched
control) to cohort with fractures (OPFx). ER,
emergency room.
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Table 2 Osteoporosis-related expenditures for the subset of patients enrolled in a fee-for-service insurance plan
Severe osteoporosis (Fracture + Osteo dx) (n = 5002) PS matched sample (n = 5830) 
% With
any use
% 
Changes
in 
utilization
Mean 
among 
users
($)
Mean 
among 
all 
patients
($)
Changes in 
expenditures
among 
all patients
($)
% With
any use
% 
Changes 
in 
utilization
Mean 
among 
users
($)
Mean 
among 
all 
patients
($)
Changes in 
expenditures
among 
all patients 
($)
Inpatient
Preperiod 0.04 9,239.89 3.69 0.00 NA NA
Study period 8.82 8.78* 8,897.73 784.47 780.77* 0.05† 0.05† 18,428.17 9.48† 9.48†
Nursing home
Preperiod 4.90 28,667.29 1,404.14 4.12 31,531.50 1,298.04
Study period 11.72 6.82* 22,048.19 2,583.02 1,178.88* 4.49† 0.37*† 33,754.83† 1,516.94† 218.9*†
Home health
Preperiod 0.28 1,052.15 2.94 0.62† 1,118.34 6.91
Study period 7.96 7.68* 568.46 45.23 42.29 2.32† 1.70*† 710.77 16.46† 9.55*†
Emergency room
Preperiod 0.04 12.42 0.00 0.02 63.72† 0.01
Study period 15.59 15.55* 136.16 21.23 21.23* 0.67† 0.65*† 60.43† 0.40† 0.39*†
Outpatient
Preperiod 8.94 200.54 17.92 10.75† 206.88 22.25
Study period 96.36 87.42* 1,392.84 1,342.16 1,324.24* 95.64 84.89*† 271.55† 259.72† 237.47*†
Outpatient pharmaceutical
Preperiod 37.11 325.46 120.76 41.25† 337.28 139.14†
Study period 54.78 17.67* 394.79 216.26 95.50* 56.24 14.99*† 424.14† 238.55† 99.42*
Total
Preperiod 43.66 3,548.72 1,549.46 48.59† 3,017.56 1,466.34
Study period 99.06 55.40* 5,039.71 4,992.36 3,442.90* 98.80 50.21*† 2,066.37† 2,041.56† 575.22*†
*P < 0.05 for comparison of preperiod costs with study period costs.
†P < 0.05 for comparison of propensity score matched cohort without fractures (matched control) with cohort with fractures (OPFx).
NA, not applicable; PS, propensity score.
Table 3 Overall expenditures for the subset of patients enrolled in a fee-for-service insurance plan
Severe osteoporosis (Fracture + Osteo dx) (n = 5002) PS Matched Sample (n = 5830) 
% 
With 
any 
use
% 
Changes
in 
utilization
Mean 
among 
users
($)
Mean 
among 
all 
patients
($)
Changes in 
expenditures
among 
all patients
($)
% 
With 
any 
use
% 
Changes
in 
utilization
Mean 
among 
users
($)
Mean 
among 
all 
patients
($)
Changes in 
expenditures
among 
all patients 
($)
Inpatient
Preperiod 13.95 13,272.35 1,852.08 9.14* 12,285.38 1,123.17*
Study period 26.45 12.50† 15,230.71 4,028.44 2,176.36† 9.01* −0.14* 12,825.18 1,154.93* 31.75*
Nursing home
Preperiod 9.16 37,205.19 3,406.63 7.58* 39,979.46 3,031.03
Study period 17.19 8.04† 31,083.15 5,344.16 1,937.53† 8.11* 0.53*† 41,571.63* 3,372.79* 341.76*†
Home health
Preperiod 39.12 4,692.50 1,835.91 38.73 3,909.72* 1,514.26*
Study period 49.34 10.22† 4,985.46 2,459.84 623.93† 41.03* 2.30*† 4,718.44 1,935.93* 421.67*†
Emergency room
Preperiod 21.31 262.49 55.94 12.68* 230.43* 29.21*
Study period 31.91 10.60† 340.99 108.80 52.86† 12.97* 0.29* 263.60* 34.18* 4.97*†
Outpatient
Preperiod 97.30 4,811.65 4,681.79 97.22 3,495.41* 3,398.29*
Study period 99.96 2.66† 7,268.60 7,265.69 2,583.90† 99.90 2.68† 4,357.85* 4,353.37* 955.08*†
Outpatient pharmaceutical
Preperiod 95.76 3,080.16 2,949.61 96.91* 2,834.51* 2,746.99*
Study period 98.28 2.52† 3,864.25 3,797.81 848.20† 97.56* 0.65*† 3,439.20* 3,355.43* 608.44*†
Total
Preperiod 99.00 14,931.21 14,781.96 99.66* 11,883.72* 11,842.96*
Study period 100.00 1.00† 23,004.74 23,004.74 8,222.78† 100.00 0.34*† 14,206.63* 14,206.63* 2,363.68*†
*P < 0.05 for comparison of propensity score matched cohort without fractures (matched control) with cohort with fractures (OPFx).
†P < 0.05 for comparison of preperiod costs with study period costs.
PS, propensity score.
an osteoporosis-related fracture and being dual-
eligible for Medicare and Medicaid, both of which
were associated with a signiﬁcant increase in total and
osteoporosis-related expenditures. Interestingly, older
patients were associated with less total expenditures
but greater osteoporosis-related costs. In addition,
patients with more comorbities as measured by the
CCI score in the preperiod were associated with higher
total expenditures but lower osteoporosis-related
costs.
Rousculp et al.150
From the multivariate ECM model, the difference in
the annual, per beneﬁciary expenses for the OPFx
study cohort versus the control cohort was $9677. Of
this amount, more than $4000 was estimated to be
related to osteoporosis-speciﬁc expenses. If the study
cohort is compared with the osteoporosis-only group,
the marginal difference in cost was $9503, with $4614
attributable to osteoporosis-speciﬁc claims. The mar-
ginal costs for the OPFx cohort were similar between
the ECM model and a log transformed OLS model.
The estimated marginal cost for the OPFx cohort with
the OLS model was $11,553 against the control group
($11,570 vs. the osteoporosis-only group). For the
subset of the study cohort who were dual-eligible, the
ECM model estimated that the marginal cost versus
the entire osteoporosis-only cohort was approximately
$11,000, with $5,300 related to osteoporosis-speciﬁc
claims. The predicted expenditures and marginal
effects associated with various fracture locations are
presented in Table 5. Predicted expenditures were
highest for hip/pelvis fractures and lowest for patients
with fractures of foot/toes.
Discussion
Information is scarce on the costs associated with oste-
oporosis in the Medicaid population. As osteoporosis
is prevalent in postmenopausal women, this study is
important not only to state Medicaid agencies, but also
to private carriers and the Centers for Medicare and
Medicaid Services (CMS). The importance to CMS is
even greater with the recent addition of Medicare cov-
erage of outpatient pharmaceuticals. In particular,
patients dually eligible for both Medicare and Medic-
aid are of high interest.
As with all claims-based analyses, there are known
issues such as the incomplete nature of the data and
the possibility of coding errors or coding omissions.
Claims data also lack detailed clinical information on
BMD results that would allow us to assess disease
severity at baseline and during the study period more
precisely. Thus, the undercoding or miscoding of data
Table 4 Exponential conditional mean model results for total expenditures and osteoporosis-related expenditures
Total expenditures Osteoporosis-related expenditures 
Parameter
estimate
Standard
error P-value
Parameter 
estimate
Standard
error P-value
Osteoporosis-related fracture 0.526 0.025 0.000 1.234 0.070 0.000
Age −0.007 0.001 0.000 0.023 0.003 0.000
Female −0.290 0.037 0.000 −0.339 0.103 0.001
State A 0.308 0.060 0.000 −0.071 0.166 0.667
State B 0.080 0.063 0.203 −1.087 0.176 0.000
Race
Black 0.027 0.054 0.626 0.215 0.147 0.143
Native American −0.414 0.234 0.077 −0.169 0.648 0.794
Hispanic 0.028 0.069 0.688 0.162 0.187 0.386
Asian −0.389 0.044 0.000 −0.471 0.122 0.000
Unknown −0.283 0.031 0.000 −0.533 0.087 0.000
Medicare dual-eligible 0.320 0.031 0.000 0.155 0.085 0.070
Eligibility reason
Aged/SSI 0.113 0.037 0.002 0.428 0.109 0.000
TANF −0.841 0.072 0.000 −0.785 0.196 0.000
Other −0.014 0.151 0.927 0.222 0.409 0.587
Plan type — PCCM −0.227 0.072 0.002 0.448 0.206 0.030
Urban −0.045 0.041 0.270 −0.147 0.115 0.202
Index year 2001 0.149 0.029 0.000 0.114 0.077 0.141
Preperiod CCI score 0.121 0.007 0.000 −0.044 0.019 0.018
Treatment (preperiod)
Alendronate (Fosamax, Merck) 0.022 0.035 0.534 −0.056 0.096 0.559
Risedronate (Actonel, P&G) −0.102 0.192 0.597 −0.398 0.521 0.446
Raloxifene (Evista, Lilly) −0.159 0.062 0.010 −0.151 0.167 0.367
Estrogen −0.107 0.032 0.001 0.036 0.089 0.690
Calcitonin (Miacalcin, Novartis) 0.243 0.046 0.000 0.424 0.126 0.001
Etidronate (Didronel, P&G) −0.140 0.284 0.621 −0.146 0.768 0.850
Constant 9.945 0.073 0.000 6.138 0.199 0.000
CCI, Charlson comorbidity index; PCCM, primary care case management; TANF/AFDC, temporary assistance for needy families/aid to families with dependent children.
Table 5 Marginal effects by types of fracture among severe
osteoporosis patients
Exponential conditional mean results 
Predicted expenditures
($)
Marginal effect
($)
Hip/pelvis 33,238.12 13,864.83
Leg/ankle 28,668.58 4,731.84
Thigh/knee 25,957.05 4,646.66
Spine 24,199.92 4,415.05
Shoulder 28,233.57 3,190.11
Trunk/ribs 21,716.82 1,991.64
Unspeciﬁed 20,583.01 1,158.45
Neck 21,271.24 645.04
Hand/ﬁngers 19,671.70 −629.32
Upper arm/elbow 24,693.71 −1,142.45
Forearm/wrist 18,982.42 −1,302.09
Foot/toes 17,704.94 −2,636.13
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may have resulted in the control group including indi-
viduals who recently had a fracture and were receiving
follow-up care that was not coded on claims, poten-
tially biasing downward the estimated incremental
cost of fracture (by biasing upward the estimates of
cost in the nonfracture group). Furthermore, the crite-
ria used for the analysis (e.g., a 1-year clean period free
of fracture) may have resulted in a more conservative
estimate of the cost burden of osteoporosis-related
fractures to Medicaid. Some patients may have
incurred a fracture before Medicaid eligibility, and as a
result of the catastrophic fracture event “spent down”
into Medicaid eligibility and after enrolling in the pro-
gram continued to receive care associated with the
fracture. An additional limitation is that for the nurs-
ing home expenses, the costs could not be allocated
speciﬁcally to osteoporosis-related items, so the entire
nursing home costs were included as osteoporosis-
related if there was a diagnosis for osteoporosis or
fracture at any point during the nursing home stay.
All patients in the databases used in this study were
derived from three unidentiﬁed Medicaid states, and
there were differences in the characteristics of the
study population from each state. Therefore, the ﬁnd-
ings from these Medicaid programs may not be appli-
cable to other state Medicaid programs. Only those
patients with fee-for-service insurance coverage were
used to estimate economic burden of illness. Although
this represented the majority of patients with oste-
oporosis, this may have introduced bias because
patients with capitated insurance coverage were
slightly younger and had fewer comorbidities.
Few studies have examined the economic burden of
osteoporosis-related fractures on Medicaid expendi-
tures. One report using data from the early 1990s
demonstrated that Medicaid expenditures increased
sharply after a fracture but found that the costs
approached baseline trends after approximately 1 year
[24]. Our results on the marginal costs after a fracture
are similar, although we did not examine the longitu-
dinal changes in expenditures beyond the annualized
estimates. Regardless, the impact of fractures due to
osteoporosis on Medicaid expenditures is substantial
and increasing the implementation of preventive strat-
egies could help ameliorate some of this burden.
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